Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $26.40.
Several research analysts have issued reports on the stock. BidaskClub upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. ValuEngine cut shares of Savara from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Canaccord Genuity set a $25.00 target price on shares of Savara and gave the stock a “buy” rating in a report on Friday, February 16th. Zacks Investment Research cut shares of Savara from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Savara in a report on Wednesday, January 3rd. They set a “buy” rating and a $35.00 target price on the stock.
Shares of Savara (SVRA) traded up $0.18 during trading on Friday, reaching $10.71. 15,662 shares of the company’s stock traded hands, compared to its average volume of 171,160. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20. Savara has a one year low of $4.60 and a one year high of $17.19. The company has a market cap of $321.78, a PE ratio of -2.56 and a beta of -0.18.
Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Savara by 642.4% in the 4th quarter. BlackRock Inc. now owns 499,512 shares of the company’s stock worth $7,412,000 after purchasing an additional 432,225 shares in the last quarter. Virtu Financial LLC acquired a new stake in Savara in the 4th quarter worth approximately $464,000. Brown Advisory Inc. acquired a new stake in Savara in the 4th quarter worth approximately $2,098,000. Geode Capital Management LLC boosted its stake in Savara by 271.7% in the 4th quarter. Geode Capital Management LLC now owns 153,388 shares of the company’s stock worth $2,276,000 after purchasing an additional 112,118 shares in the last quarter. Finally, Sectoral Asset Management Inc acquired a new stake in Savara in the 4th quarter worth approximately $2,374,000. Institutional investors and hedge funds own 38.25% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3261393/savara-inc-svra-receives-26-40-consensus-price-target-from-brokerages.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.